Immune Dysregulation in Down Syndrome: Implications for Infectious Susceptibility and Vaccine Response Authors: Sofía Solari-Hernández, Enrique González-Madrid, Pablo A González, Susan M Bueno, Alexis M Kalergis Published: 2026 ABSTRACT AbstractDown syndrome (DS), caused by trisomy 21, is characterized by complex immune dysregulation that increases susceptibility to infections and alters vaccine responsiveness. Gene dosage effects involving interferon receptor loci on chromosome 21 contribute to chronic type I interferon hyperactivation, sustained JAK-STAT signaling, and persistent expression of interferon-stimulated genes. This baseline inflammatory state is accompanied by quantitative and functional defects in both innate and adaptive immunity, including impaired neutrophil chemotaxis, pro-inflammatory monocyte polarization, reduced naïve T- and B-cell compartments, restricted antigen receptor diversity, diminished class-switched memory B cells, and features of accelerated immunosenescence. Clinically, these immune alterations are associated with an increased risk of severe respiratory viral infections, such as respiratory syncytial virus, influenza, and SARS-CoV-2, as well as reduced magnitude and durability of vaccine-induced immunity. Cohort studies in both pediatric and adult populations have reported higher rates of hospitalization and mortality, along with lower peak antibody titers and more rapid waning of immunity following vaccination. This review integrates molecular, cellular, and clinical evidence to define the interferon-driven immune phenotype in DS and its implications for susceptibility to infection and vaccination response. A mechanistic understanding of this immune landscape provides a framework for developing tailored preventive strategies and optimizing vaccination approaches in this vulnerable population.Keywords: Down syndrome, Immune alterations, Interferon signaling, Infectious susceptibility, Vaccination response Introduction Down syndrome (DS), also known as trisomy 21, results from the presence of a complete or partial third copy of chromosome 21 [1, 2]. This chromosomal abnormality leads to gene overexpression, affecting numerous biological processes, including neurodevelopment, endocrine function, metabolism, and immunity [1, 2]. In most cases, complete trisomy 21 arises from meiotic nondisjunction, a process that occurs more frequently in oocytes from older women [3]. The prevalence of DS varies across countries and is influenced by maternal age, access to prenatal screening, and national legislation on pregnancy termination [4]. Estimated rates range from 0.3 to 2.9 per 1,000 live births, likely underestimated due to elective terminations after prenatal diagnosis [5]. In Chile, a rising trend was reported, with an average of 2.47 per 1,000 live births between 1998 and 2005 [6]. In contrast, lower rates in countries such as France and Spain have been attributed to earlier prenatal detection and legal abortion policies [7]. Over the past several decades, accumulating evidence has shown that trisomy 21 results in complex, multidimensional immune alterations that disrupt immune homeostasis from early development. Trisomy 21 has therefore been proposed as a form of primary immunodeficiency characterized by immune dysregulation [8, 9]. These abnormalities encompass impaired lymphocyte maturation, altered immune cell subpopulations, dysregulated cytokine production, and persistent activation of type I interferon signaling pathways [10–13]. Collectively, these defects are associated with a maladaptive immune phenotype marked by increased susceptibility to both common and severe infections [14], elevated risk of autoimmunity, persistent low-grade inflammation, and diminished vaccine responses [11, 15]. While these findings have led to a reassessment of clinical monitoring and preventive strategies for individuals with DS, significant gaps remain in understanding the specific cellular and molecular mechanisms underlying this immune imbalance and its progression throughout the lifespan. This review synthesizes current evidence regarding the molecular and cellular basis of immune dysregulation in DS, with particular emphasis on interferon-driven pathways and alterations in both innate and adaptive immunity. It further examines how these mechanisms contribute to increased infection risk, immune-mediated comorbidities, and reduced vaccine efficacy compared with euploid populations. Immune Response in Down Syndrome DS is characterized by complex, multilayered immune dysregulation affecting both innate and adaptive immune compartments and is associated with increased susceptibility to infections, altered inflammatory responses, and reduced vaccine efficacy. In this section, we outline the key immune elements altered in individuals with DS. Figure 1; Table 1 provide an overview of the main cellular, molecular, and signaling abnormalities, along with their functional consequences and clinical relevance. Interferon-driven immune dysregulation in Down syndrome. Conceptual three-column model comparing euploid individuals and individuals with Down syndrome (DS). Euploid: regulated basal immune tone with infection-triggered activation; intact neutrophil function, balanced monocyte responses, preserved NK cytotoxicity, controlled complement activity, and transient, tightly regulated interferon (IFN)-JAK-STAT signaling, supporting effective pathogen clearance and durable vaccine responses. Trisomy 21 (mechanistic axis): increased gene dosage of IFN receptor subunits (IFNAR1, IFNAR2, IFNGR2, IL10RB) leads to enhanced IFN sensitivity, sustained JAK-STAT activation (notably STAT1), and elevated interferon-stimulated gene expression, serving as a central driver of immune dysregulation. Down syndrome: chronic immune activation with persistent low-grade inflammation; impaired neutrophil function, pro-inflammatory monocyte skewing, increased but functionally reduced NK cells, reduced NKT regulatory capacity, complement activation, decreased naïve T cell output and repertoire diversity, early T cell immunosenescence, Th1/Th17 CD4⁺ polarization with impaired Treg function, and reduced naïve B cells with weakened antigen-specific antibody responses, clinically associated with increased respiratory infections, selected inflammatory hypersensitivity manifestations, and suboptimal vaccine immunity. Arrows (↑/↓) indicate the direction of change in DS relative to euploid controls, based on consistent findings reported in the literature, and represent overall trends rather than quantitative measures of statistical significance. The schematic is an original figure created by the authors and was made with Biorender.com Table 1Immune alterations in Down syndromeImmune componentAlteration in Down syndromeConsequence for host defenseInterferon signalingTriplication of IFN receptor subunits; chronic JAK-STAT activation; elevated interferon-stimulated genes (ISGs)Persistent immune activation and impaired resolution; dysregulated antiviral responses; potential contribution to systemic and neuroinflammatory processesNeutrophilsImpaired chemotaxis and effector functionReduced early bacterial clearanceMonocytesPro-inflammatory skewing; altered TLR responsesExaggerated inflammation; impaired pathogen sensingComplementBasal activation with altered regulatory balanceChronic inflammation; potential tissue damage; contribution to neuroinflammation and susceptibility to neurodegenerative processesNK cellsIncreased frequency but reduced basal cytotoxicitySuboptimal antiviral and tumor surveillanceCD8⁺ T cellsReduced naïve pool; restricted TCR repertoire; early exhaustionImpaired viral clearance; limited memory formationCD4⁺ T cellsTh1/Th17 polarization; reduced naïve compartment; impaired regulatory balanceChronic inflammation; reduced responses to novel pathogens; lower tolerance threshold predisposing to autoimmunity and selected inflammatory hypersensitivity manifestationsTregsIncreased frequency but impaired suppressionLoss of immune regulation; inflammatory amplificationTfh cellsExpanded but functionally impairedDefective germinal center responsesB cells and antibody responsesReduced naïve and memory B-cell subsets; decreased class-switched memory B cells; impaired germinal center support; diminished antigen-specific immunoglobulin productionWeakened primary and recall antibody responses; impaired responses to polysaccharide vaccines with relatively preserved responses to protein-based vaccines Immune alterations in Down syndrome Innate Immunity Recruitment and Function of Phagocytic Cells Individuals with DS exhibit significant alterations in innate immune function, particularly in phagocytic cells such as neutrophils and monocytes, which play key roles in detecting and eliminating pathogens [16]. Although the absolute neutrophil count is generally within normal limits, several studies have reported consistent functional deficiencies in these cells [16]. Notably, chemotaxis is reduced, indicating a diminished ability to efficiently migrate to sites of infection or inflammation [17]. While basal expression of adhesion molecules such as CD11b does not appear reduced, neutrophils from individuals with DS show increased CD11b expression following lipopolysaccharide stimulation, suggesting an exaggerated response to inflammatory stimuli. In addition, intracellular calcium signaling dysfunctions have been reported that may impair proper regulation of the phagocytic process [17, 18]. Monocytes also display relevant changes. A higher proportion of non-classical monocytes has been observed, which exhibit a proinflammatory profile and are associated with sustained production of cytokines such as IL-6 and TNF-α [11, 16, 17]. Although expression of major histocompatibility complex class II (MHC-II) molecules may be elevated, the functional response of monocytes to stimuli such as Toll-like receptor (TLR) ligands is markedly attenuated, suggesting partial impairment of inflammatory signaling pathways [11, 16, 17]. Interferon Hypersensitivity A hallmark of innate immunity in people with DS is the chronic activation of the type I interferon (IFN-I) axis [19]. This persistent activation is primarily driven by the triplication of genes encoding interferon receptor subunits on chromosome 21, including IFNAR1, IFNAR2, IFNGR2, and IL10RB, which mediate responses to type I, II, and III interferons, respectively [19, 20]. The overexpression of these receptors renders immune cells hypersensitive to interferons, leading to sustained activation of the JAK-STAT signaling pathway, particularly STAT1 [19, 20]. In DS, this leads to increased ISG expression even in the absence of infectious stimuli, thereby establishing a state of chronic immune activation. Conceptually, this persistent interferon-driven signaling resembles gain-of-function (GOF) STAT mutations, which are marked by prolonged pathway activation and are frequently associated with autoimmunity and chronic inflammation [21, 22]. In contrast, loss-of-function (LOF) mutations in JAK-STAT components impair cytokine signaling. These mutations are typically associated with immunodeficiency, underscoring the importance of tightly regulated pathway activity for immune homeostasis [23, 24]. Although chronic interferon activation in DS may confer some antiviral advantages, its persistence contributes to low-grade inflammation and immune dysregulation, features reminiscent of monogenic interferonopathies [19, 20]. Consistent with a causal role for interferon signaling, studies in murine models have shown that normalizing interferon receptor gene dosage restores immune responses and ameliorates DS-associated phenotypes [25]. These insights have significant therapeutic implications, with pharmacologic inhibition of JAK kinases emerging as a potential strategy to modulate interferon-driven immune dysregulation in DS [26]. Early-phase clinical studies have begun to evaluate this approach in individuals with DS. In a recent phase II clinical study, treatment with the JAK inhibitor tofacitinib demonstrated a favorable safety profile. It was associated with reductions in interferon signatures, circulating cytokines, and pathogenic autoantibodies [27]. These molecular changes were accompanied by clinical improvement in autoimmune and inflammatory manifestations, including dermatologic conditions such as alopecia areata, psoriasis, and atopic dermatitis [27]. Notably, these effects were achieved without evidence of broad immunosuppression, suggesting that JAK inhibition can selectively dampen dysregulated signaling pathways [27]. Although these findings remain preliminary, they support the concept that targeted modulation of the JAK-STAT pathway may represent a promising therapeutic avenue in DS. Further studies are needed to define long-term safety, optimal timing of intervention, and the broader impact of JAK inhibition on immune function and disease susceptibility in this population. Complement System The complement system is a critical pathway of innate immunity, comprising a series of plasma proteins that circulate in an inactive state and are activated in a cascade upon encountering pathogens [28]. Its activation leads to essential immune processes, including microbial opsonization, recruitment of inflammatory cells, and formation of the membrane attack complex (MAC), which directly lyses pathogenic cells [28]. Additionally, the complement system plays key roles in the clearance of apoptotic cells and the modulation of both inflammatory and adaptive immune responses [28]. Studies have shown that people with DS exhibit elevated plasma levels of complement components, including C1q, C3, and C9, as well as activation products such as iC3b and the terminal complement complex (TCC) [16, 29]. At the cellular level, studies in astrocytes derived from induced pluripotent stem cells (iPSCs) of individuals with DS have revealed overexpression of complement-related genes, including C1R, C1S, C4A/B, C5, and C9, as well as inflammatory receptors such as C5aR1, along with increased secretion of C4 [30]. This indicates intrinsic complement activation within the central nervous system, which may contribute to inflammation and increased susceptibility to neurodegenerative processes in DS. In this context, the markedly elevated lifetime risk of early-onset neurodegeneration in DS, particularly Alzheimer’s disease, underscores how chronic immune activation can extend beyond peripheral defenses and disrupt central nervous system homeostasis [31, 32]. Accumulating evidence suggests that sustained activation of immune pathways, including complement activation, interferon signaling, and dysregulated cytokine production, may create a pro-inflammatory environment within the brain, promoting microglial activation, synaptic dysfunction, and neuronal vulnerability [33, 34]. Microglial dysfunction and increased interferon signaling have been directly linked to synaptic alterations and cellular senescence in DS-associated Alzheimer’s disease [33], while complement activation has emerged as a key driver of neuroinflammation and neuronal injury in neurodegenerative conditions [34]. These observations support the concept that neurodegeneration in DS is not solely a consequence of gene dosage effects but also reflects the interplay between intrinsic genetic factors and chronic immune dysregulation [8, 29]. Indeed, complement dysregulation in DS has been associated with Alzheimer’s disease risk, reinforcing the link between immune activation and neurodegenerative outcomes [8, 29]. NK and NKT Cells Natural killer (NK) cells are key components of the innate immune system, responsible for eliminating infected or malignant cells and modulating adaptive immune responses [35]. In individuals with DS, quantitative and functional alterations have been identified in this cell population [36, 37]. Several studies have reported an increased relative proportion of NK cells, particularly in children under 2 years of age, in whom they can comprise up to 10.3% of circulating lymphocytes, compared with approximately 5.7% in euploid children [36, 37]. However, this numerical increase does not consistently translate into enhanced immune efficacy [36, 37]. In fact, studies have shown reduced spontaneous cytotoxic capacity, as assessed by lysis of target cells such as the K562 cell line [36, 38]. This functional impairment can be partially reversed by cytokine stimulation with IL-2, IFN-β, or IFN-γ, indicating that NK cells in DS retain recoverable functional potential [16, 39]. Additionally, NK cells from individuals with DS show heightened sensitivity to type I interferons, particularly IFN-α, which may enhance their activation under specific conditions. However, this response appears to depend on both the cellular environment and the individual’s age [16, 39]. Natural killer T (NKT) cells, in contrast, have been less extensively studied in the context of DS. However, available evidence suggests both numerical and functional reductions in individuals with trisomy 21 [37]. Given the regulatory role of NKT cells in maintaining immune homeostasis, such alterations may contribute to a chronic proinflammatory state, reduced efficiency in controlling intracellular pathogens, and an increased predisposition to autoimmune diseases [40]. Collectively, this dysregulated innate immune profile likely contributes to the increased susceptibility to infections and broader immune dysfunction observed in individuals with DS. Adaptive Immunity In DS, adaptive immunity is characterized by multifactorial alterations that compromise both its effectiveness and homeostatic balance. These dysfunctions affect both the cellular and humoral branches of the immune response, reflecting a combination of immunodeficiency, premature immunosenescence, and persistent inflammation (Fig. 1; Table 1). Thymic Structure, Central Tolerance, and Thymic Output in Down Syndrome The thymus plays a central role in shaping adaptive immunity by supporting thymocyte development, selection, and central tolerance [41]. In individuals with DS, multiple studies indicate that thymic dysfunction is an early and significant component of immune dysregulation. Structural analyses have shown that the thymus in individuals with DS is frequently reduced in size and exhibits abnormal organization, including cortical atrophy, impaired corticomedullary demarcation, and features consistent with premature involution [42, 43]. These structural changes are accompanied by alterations in the thymic epithelial compartment, which is essential for thymocyte maturation and selection, including abnormalities in medullary organization and thymocyte distribution [44]. At the molecular level, alterations in the thymic epithelial compartment have been reported in DS. The autoimmune regulator (AIRE), a transcription factor expressed by medullary thymic epithelial cells (mTECs), plays a central role in establishing central tolerance by promoting the expression of tissue-restricted antigens required for the negative selection of autoreactive T cells [45]. Dysregulation of AIRE has been reported in the thymus of individuals with DS, with evidence of altered expression and increased frequencies of AIRE-positive mTECs and dendritic cells, depending on the cohort and developmental stage examined [46, 47]. In addition to these molecular alterations, structural changes in the medullary compartment have been described, including enlarged Hassall’s corpuscles, particularly in the thymus of DS infants [46, 47]. Together, these findings suggest disruption of thymic stromal organization and indicate that both molecular and structural alterations of the thymic microenvironment may contribute to impaired central tolerance and increased susceptibility to autoimmunity in DS [46, 47]. Functionally, these structural and molecular alterations are associated with reduced thymic output. Studies using signal-joint T-cell receptor excision circles (sjTRECs) and recent thymic emigrants (RTEs) have consistently shown that children with DS exhibit significantly reduced production of naïve T cells compared to age-matched controls [43, 48]. This reduction contributes to the contraction of the naïve T cell pool and to the limited diversity of the TCR repertoire observed in both CD4⁺ and CD8⁺ compartments [43, 48]. Studies in both experimental models and human thymic systems have shown that interferon signaling plays a regulatory role in thymic biology. Specifically, tonic type I interferon signaling contributes to the late stages of thymocyte maturation, supporting the transition of positively selected thymocytes into fully functional naïve T cells [49]. In addition, constitutive production of type I and type III interferons by subsets of mTECs has been shown to shape the thymic microenvironment by promoting the activation and maturation of antigen-presenting cells and by supporting regulatory T cell selection and T cell receptor repertoire diversity [50]. In the context of DS, this potential link remains partly hypothetical because direct mechanistic studies are still limited. However, it is supported by converging lines of evidence. First, trisomy 21 is associated with constitutive activation of the interferon pathway due to gene dosage effects on interferon receptors, resulting in a chronic interferon-driven state [19]. Second, altered interferon-related cytokine expression, including increased IFN-γ-producing cells, has been documented in the thymus of individuals with DS and is associated with abnormalities in thymic architecture and thymocyte maturation [51]. More recent transcriptomic analyses further support the presence of enhanced interferon signaling signatures in DS thymic tissue, alongside structural and cellular alterations [42]. Taken together, these observations suggest that dysregulated interferon signaling may be a mechanistically plausible contributor to thymic dysfunction in DS. However, its specific impact on thymocyte selection and central tolerance remains to be fully characterized. CD8⁺ T Cells CD8⁺ T cells are essential components of adaptive immunity, responsible for the specific elimination of virus-infected or transformed cells through recognition of antigens presented by major histocompatibility complex class I (MHC-I) molecules [52]. In individuals with DS, these cells exhibit several alterations that impair their immune function. First, a reduction in thymic output of naïve cells has been described, manifested by a lower proportion of CD8⁺ recent thymic emigrants and limited clonal expansion, suggesting a restricted T-cell receptor (TCR) repertoire and a diminished capacity to respond to novel antigens [53]. This deficit is consistent with altered thymic function in DS, as reflected by reduced thymic output and diminished generation of naïve T cells from early life [48]. Second, CD8⁺ T cells in people with DS tend to acquire a sustained activation phenotype and features of premature immunosenescence, as evidenced by increased expression of inhibitory molecules such as PD-1, CD244, CD160, and KLRG1, associated with functional exhaustion [53]. Recent transcriptomic data indicate that the triplication of the interferon receptor cluster (IFNAR) on chromosome 21 is associated with chronic interferon signaling, which has been proposed to promote a senescent state characterized by CD57 expression [54, 55]. Third, although these cells retain the ability to produce effector cytokines and granzyme B in response to viral stimuli, a higher frequency is required to achieve a response comparable to that of individuals without trisomy 21, suggesting reduced functional efficiency [53]. Additionally, chronic exposure to persistent pathogens may promote the expansion of clonal CD8⁺ T-cell lineages with altered epigenetic features, further limiting repertoire diversity and reducing functional plasticity [53]. This remodeling of the T-cell compartment is associated with an inverted CD4/CD8 ratio, a hallmark of advanced immune aging that is frequently observed in young adults with DS [19, 55]. CD4⁺ T-cell Polarization and Regulatory Dysfunction CD4⁺ T cells play a central role in coordinating the adaptive immune response by facilitating B cell activation, supporting CD8⁺ T cell expansion, and regulating inflammation through cytokine production [56]. In individuals with DS, studies have documented quantitative and functional alterations in these cells that contribute to the immune dysfunction observed in this population [55]. A decreased proportion of naïve CD4⁺ T cells has been reported, along with an expansion of effector memory cells, indicating an early immunosenescent phenotype [19, 55]. This reduction in the naïve pool is associated with a diminished capacity to respond to novel antigens, thereby weakening the efficacy of primary immune responses [19, 55]. Functionally, conventional CD4⁺ T cells in DS exhibit altered effector subset polarization, with a bias toward pro-inflammatory profiles. In particular, an increased frequency of Th1 and Th17 cells, producers of IFN-γ and IL-17, respectively, has been described, potentially contributing to the chronic low-grade inflammation characteristic of trisomy 21 [19, 55, 57]. Additionally, these cells exhibit elevated expression of activation and exhaustion markers, such as HLA-DR and PD-1, suggesting sustained but functionally limited activation in response to antigenic challenges [19, 55, 57]. As for regulatory T cells (Tregs), which normally suppress excessive immune responses and maintain peripheral tolerance, available evidence, though still limited, consistently indicates an increased frequency of these cells in the peripheral blood of individuals with DS [57, 58]. However, this increase does not appear to translate into more effective suppressive function [57, 58]. On the contrary, functional studies have shown that Tregs in DS exhibit diminished ability to suppress effector T-cell proliferation and inflammatory cytokine production, potentially contributing to a dysregulated immune environment prone to autoimmune phenomena [57, 58]. This apparent paradox, an increased frequency of Tregs alongside impaired suppressive function, suggests that Tregs in DS are quantitatively expanded but qualitatively dysfunctional [58]. As a result, rather than enhancing immune regulation, Tregs in DS may have a reduced capacity to adequately control effector responses, thereby contributing to persistent inflammation and increased susceptibility to autoimmune disease [58]. Importantly, Tregs exert a broad range of functions beyond classical immunosuppression. In addition to maintaining peripheral tolerance, Tregs play key roles in tissue homeostasis, repair, and regeneration, and actively modulate local immune environments through context-dependent interactions with non-immune cells [59]. Although these pleiotropic functions have not been fully characterized in DS, their disruption may further contribute to the complex immunopathology associated with trisomy 21. The thymus plays a central role in the development and functional programming of Tregs, and thymic abnormalities described in DS may contribute to both abnormal Treg generation and defective functional maturation [44]. Consistent with this, a study has shown that Tregs derived from both thymic tissue and peripheral blood in individuals with DS exhibit reduced suppressive activity [58], supporting the concept that thymic dysfunction may underlie qualitative defects in this population. Beyond quantitative and functional alterations in conventional and regulatory CD4⁺ T cells, these adaptive immune imbalances have important clinical correlates. Individuals with DS exhibit a markedly increased susceptibility to autoimmune diseases, with a 4-6-fold higher risk of developing common conditions such as autoimmune thyroid disease, celiac disease, and type 1 diabetes compared with the general population [60]. Autoimmune thyroiditis alone affects up to one-third of children with DS, and multiple autoimmune conditions frequently co-occur within the same individual, often with earlier onset and increased clinical aggressiveness [60, 61]. Mechanistically, this pro-autoimmune phenotype reflects convergent defects in central and peripheral tolerance. These mechanisms are consistent with alterations in central tolerance, for which thymic abnormalities, including altered AIRE expression and structural defects, have been described in individuals with DS, potentially facilitating the escape of autoreactive T cells into the periphery [60, 62]. The chronic interferon-driven state in DS, sometimes described as a mild interferonopathy, is associated with sustained immune activation that may lower the threshold for loss of tolerance [15, 19, 55, 57]. Importantly, genetic normalization of interferon receptor dosage in trisomic mouse models restores immune parameters, and pharmacologic JAK inhibition has been associated with attenuation of inflammatory signatures in individuals with DS, supporting a potential causal role for interferon hyperactivation [15, 19, 55, 57]. In contrast to the well-established autoimmune predisposition, allergic and atopic manifestations in DS appear to follow a distinct pattern [63]. Rather than a classic Th2-dominant phenotype, individuals with DS demonstrate a predominance of Th1/Th17 polarization within a background of interferon hyperresponsiveness [63]. Nevertheless, selected allergic conditions, particularly non-IgE-mediated gastrointestinal food allergies such as food protein-induced enterocolitis syndrome (FPIES), are reported at increased frequencies, with more severe clinical presentations compared with the general pediatric population [64–66]. Respiratory manifestations, including airway hyperresponsiveness and persistent obstructive sleep apnea, further suggest that structural airway factors combined with immune dysregulation may amplify inflammatory responses [67–69]. Experimental data from trisomic mouse models (Ts65Dn) support heightened immune-respiratory sensitivity and altered lymphocyte composition, reinforcing the concept that trisomy 21 modifies barrier and cytokine responses to environmental antigens [70]. In addition to lymphocyte dysfunction, individuals with DS exhibit marked alterations in hematopoiesis, resulting in a characteristic predisposition to leukemic disorders. Children with DS have a substantially increased risk of developing acute leukemia, particularly in early childhood. This includes an approximately 10- to 20-fold higher risk of acute lymphoblastic leukemia (ALL) and a markedly higher risk, estimated between 150- and 500-fold, of acute myeloid leukemia (AML) compared with children without DS [71–74]. This increased susceptibility is especially pronounced in infancy and early childhood and reflects fundamental perturbations in fetal and early-life hematopoiesis associated with trisomy 21. A defining feature of DS is transient abnormal myelopoiesis (TAM), a self-limited neonatal myeloproliferative disorder observed in approximately 5–10% of newborns with DS [75, 76]. TAM is characterized by the clonal expansion of immature megakaryoblasts. It is strongly associated with somatic mutations in the GATA1 transcription factor, which arise in the context of trisomy 21-driven alterations in fetal liver hematopoiesis [77, 78]. Although most cases resolve spontaneously within the first months of life, approximately 10–20% of affected individuals subsequently develop DS-associated myeloid leukemia during early childhood, highlighting TAM as a pre-leukemic condition [77, 78]. These findings illustrate how trisomy 21 directly alters early hematopoietic development and lineage commitment, providing a well-established example of how gene-dosage effects on chromosome 21 reshape immune-hematopoietic interactions and contribute to the unique disease susceptibility profile of individuals with DS. B Cells and Antibodies B cells play a fundamental role in adaptive humoral immunity, contributing to antibody production, antigen presentation, and the establishment of immunological memory [79]. In people with DS, a profound dysfunction of this lymphocyte population has been documented, encompassing developmental abnormalities and deficiencies in effector functions [10]. Transcriptomic and phenotypic studies have shown a significant reduction in B cell production within the bone marrow, reflected in a lower frequency of mature circulating B lymphocytes in peripheral blood [80]. This decrease is particularly notable in the naïve B cell subset, whose scarcity compromises the immune system’s ability to mount effective primary responses against novel antigens [10, 81]. Moreover, memory B cells in individuals with DS exhibit alterations in both abundance and function. Although some subpopulations display a more activated phenotype, their differentiation into high-affinity antibody-producing plasma cells is less efficient [10, 81]. This dysfunction has been linked to deficiencies in germinal center formation, structures essential for affinity maturation and the selection of specific B cell clones [10, 81]. Mechanistically, these defects may be driven by impaired signaling through the B cell receptor (BCR) and the IL-21 receptor, as well as suboptimal interactions with follicular helper T (Tfh) cells, which are critical for providing functional support to B cells during adaptive immune responses [10, 81]. Additionally, an abnormal expansion of transitional B cells and autoreactive lineages has been reported in individuals with trisomy 21, potentially facilitating the breakdown of peripheral tolerance and the development of autoimmune phenomena [53, 80]. Functionally, individuals with DS show reduced production of antigen-specific immunoglobulins following vaccination and in response to common infections, indicating a diminished capacity to generate robust, long-lasting humoral responses [10, 81]. Antibody production is a critical function of the adaptive humoral immune response, mediated by plasma cells derived from activated B lymphocytes [79]. In DS, both quantitative and qualitative alterations in the humoral response have been described, reflecting upstream dysfunctions in B- and T-cell activation, differentiation, and cooperation [10, 53, 81]. From a serological perspective, the immunoglobulin profile in individuals with DS can vary, but one of the most consistent alterations is a reduction in IgM levels, particularly during early life [10, 82]. IgM is essential for primary and T cell-independent responses, and its deficiency suggests impaired activation of naïve B cells and reduced maturation into effective plasma cells [79]. In contrast, IgA and IgG levels are typically normal or even elevated in some cases, although these concentrations do not necessarily reflect adequate functional responses [10, 53, 81]. Furthermore, the antibody repertoire in DS displays reduced diversity, a low rate of somatic hypermutation, and, in some cases, the presence of autoantibodies [83]. These features indicate a loss of immunological tolerance and may contribute to the increased incidence of autoimmune diseases in this population [53]. Such defects suggest a malfunction in germinal center processes, where antibody specificity and affinity are refined [10, 53, 81]. Altogether, impairments in antibody production, specificity, and persistence in DS represent an important component of adaptive immune dysfunction. These deficiencies are not only associated with increased susceptibility to infections but also compromise the effectiveness of preventive strategies such as vaccination and contribute to the development of pathological immune responses [10, 18, 53, 81]. Respiratory and Viral Infections in Down Syndrome Increased Susceptibility to Respiratory Infections Infectious diseases are caused by pathogenic microorganisms that can be transmitted between individuals and can result in high mortality, disability, or global spread [84]. In people with DS, immunological alterations are associated with increased susceptibility to and severity of respiratory viral infections, making them a clinically significant concern [85, 86]. In fact, pneumonia secondary to respiratory infections in individuals with DS represents a major contributor to morbidity and mortality, particularly during childhood [85, 86]. This heightened vulnerability likely reflects a combination of the global burden of respiratory pathogens and biological characteristics of DS, including immune dysregulation and common comorbidities that amplify the clinical impact [87]. The most frequently reported conditions include pneumonia, respiratory syncytial virus (RSV) bronchiolitis, influenza, coronavirus disease 2019 (COVID-19), and recurrent otitis media [86, 88]. Children with DS have been reported to become ill more frequently, experience longer and more severe disease courses, require more intensive support, and have higher readmission rates due to recurrence or bacterial superinfection [86, 88]. This increased clinical burden is supported by cohort studies evaluating hospitalization and mortality. In a pediatric cohort, comorbidities typically associated with DS, including congenital heart disease, anatomical airway abnormalities, and gastroesophageal reflux, were associated with increased hospital admission and poorer caregiver-reported quality of life [89]. Evidence from children with congenital heart disease, a highly prevalent comorbidity in DS, further demonstrates that respiratory infections are a major cause of hospitalization in early childhood [90] (Table 2). Table 2Respiratory infection risk and preventive strategies in Down syndromePathogenIncreased Clinical Risk in DSVaccine/Prophylaxis PlatformKey Limitation in DSRecommended StrategyRSV3-7x higher hospitalization; increased ICU admission; documented mortality in childrenPassive monoclonal antibodies (palivizumab; long-acting agents)Severe disease despite immune activation; comorbidity amplificationConsider seasonal monoclonal prophylaxis in infants and high-risk childrenInfluenzaIncreased hospitalization and intubation risk; elevated mortality in pandemic seasonsInactivated influenza vaccines (standard or enhanced formulations)Reduced durability and qualitative antibody defectsAnnual vaccination; consider high-dose/adjuvanted vaccines in adultsSARS-CoV-2~ 4-5x higher hospitalization; ~10x higher mortality in adults; earlier age of severe diseasemRNA and vector-based vaccinesLower peak antibody titers and faster waning; preserved but reduced T-cell magnitudeEarly and additional booster doses; prioritize adults > 40 years Streptococcus pneumoniae Increased pneumonia and invasive disease burdenConjugate vaccines ± polysaccharideVariable polysaccharide response; limited IgG2 and memory B cellsPrefer conjugate-first strategy; ensure full schedule and sequential coverage Respiratory infection risk and preventive strategies in Down syndrome Respiratory Syncytial Virus (RSV) RSV bronchiolitis is consistently reported as a major contributor to hospitalization among children with DS [86, 88]. Studies have reported increased disease severity, prolonged hospital stays, and higher complication rates in this population [91–93]. The presence of congenital heart disease and structural airway abnormalities is associated with increased RSV severity in children with DS [89, 90]. Globally, RSV is recognized as a leading cause of acute lower respiratory tract infection (ALRI) and bronchiolitis in early childhood [94]. Multiple studies have shown that RSV infection in individuals with DS is associated with significantly higher hospitalization rates, extended hospital stays, and increased disease severity compared to euploid children [95–97]. Population-based analyses have shown that children with DS experience substantially elevated rates of RSV-associated hospital admissions. For example, a large cohort study encompassing over 3.2 million person-years found an RSV hospitalization rate of 9.6% in children with DS, compared to 2.8% in controls, with an adjusted hazard ratio (HR) of 3.46 (95% CI 2.75–4.37), even after adjusting for other risk factors [93, 98]. Meta-analyses estimate that infants with DS have an approximately 6.8-fold increased relative risk (RR) of RSV-associated hospitalization compared to unaffected children under two years of age (117.6 vs. 15.2 per 1000 child-years) [99]. Prospective cohort studies are consistent with these findings: in a matched study of term infants, RSV-related hospitalization was significantly more frequent in the DS group than in non-DS infants (9.7% vs. 1.5%, P = .03) [100], and the proportion of acute lower respiratory infection admissions was markedly higher in the DS group (44.1% vs. 7.7%, P < .0001) [100]. Beyond hospitalization rates, RSV disease in DS is associated with increased severity. Hospitalized children with DS require longer stays and are more likely to need respiratory support, with relative risks for assisted ventilation estimated at approximately 5.8 times higher than in controls [96, 101]. Systematic reviews consistently indicate that DS independently is linked to more severe RSV-associated ALRI, with risk comparable to or exceeding that of other established factors such as congenital heart disease or bronchopulmonary dysplasia [95]. Immunoprophylaxis with palivizumab, a monoclonal antibody against RSV, has been evaluated in children with DS. Registry data indicate that palivizumab is associated with a 3.6-fold reduction in the incidence rate ratio of RSV-related hospitalizations among DS children during the first two years of life compared with untreated DS children [102, 103]. In some cohorts, DS infants receiving palivizumab exhibited lower rates of RSV hospitalization (approximately 3.0% vs. 15.0% among those without prophylaxis) [102, 103]. However, randomized controlled trials specifically in DS populations have not yet been conducted. Although formal guidelines remain limited, these findings suggest that RSV prophylaxis may be considered for high-risk children with DS. Furthermore, international cohort data indicate that RSV infection in children with DS may be associated with RSV-related mortality even in the absence of other classic risk factors, with a notable proportion of fatal RSV cases occurring in this group [91, 100]. Influenza Virus Influenza is one of the most frequently reported respiratory infections in individuals with DS and is associated with increased healthcare utilization and complications [85]. Seasonal influenza is a well-established cause of morbidity and mortality across populations, with evidence suggesting that this risk may be higher in people with DS [104]. While large cohort estimates specific to DS remain limited, data from the 2009 H1N1 pandemic suggest increased hospitalization and mortality in this population [85, 104, 105]. During this outbreak, individuals with DS had higher odds of hospital admission (crude OR approximately 15.9), endotracheal intubation (OR approximately 8.2), and death (crude OR approximately 33.5) compared with age-matched controls without DS [85, 104, 105]. These associations persisted after adjustment for age and sex [85, 104, 105]. Although data on seasonal influenza in DS are sparse, global surveillance from the Influenza Hospitalization Surveillance Network indicates that among hospitalized, laboratory-confirmed influenza cases in the general population, in-hospital mortality is approximately 2.7% and ICU admission is about 5.1%, increasing with age and comorbid conditions [106–108]. Given the higher baseline susceptibility and comorbidity burden in DS, these benchmarks suggest that influenza may pose a disproportionately high clinical risk in this population [106–108]. Collectively, these findings suggest that influenza may be associated with more severe outcomes in DS compared with the general population, including a higher likelihood of hospitalization, increased need for intensive care, and elevated mortality risk, particularly during pandemics or seasons with more virulent strains. SARS-CoV-2 COVID-19 has been associated with increased rates of hospitalization and mortality in individuals with DS compared with euploid populations [109, 110]. Large cohort studies suggest that adults with DS have elevated risks of severe disease and death following SARS-CoV-2 infection [109, 110]. In the UK, hazard ratios for COVID-19-related hospitalization among adults with DS were approximately 4.94 compared with individuals without DS, and COVID-19 accounted for ~ 39.7% of all deaths in the DS cohort versus ~ 20.3% in the general population [111]. Adjusted mortality hazard ratios remained markedly elevated at around 10.39 after accounting for age, sex, ethnicity, body mass index, and comorbidities [111]. Hospital-based data indicate that adults with DS hospitalized for COVID-19 tend to be younger at the time of admission, have longer hospital stays, higher rates of mechanical ventilation, and increased mortality (25% vs. ~ 6.7%) compared with non-DS patients [110]. Pediatric registry data from Brazil indicate that hospitalized children with DS had higher odds of death (OR = 1.82; 95% CI 1.22–2.68) and longer recovery times than non-DS hospitalized children with COVID-19 [112]. Further analyses indicate that mortality rates among DS patients with COVID-19 are higher, particularly in adults over 40 years of age [113]. In one study, in-hospital mortality reached 26.7% in DS patients with COVID-19, rising to 37% in those over 40 years, compared with approximately 9.7% for non-COVID pneumonias in DS [113]. Overall, these data suggest that SARS-CoV-2 infection is associated with increased risks of hospitalization, severe disease progression, and mortality in individuals with DS, with age-related vulnerability and worse in-hospital outcomes independent of many traditional risk factors. Vaccine Responses in DS: Mechanistic and Clinical Evidence General Alterations in Vaccine Response Individuals with DS often exhibit suboptimal responses to multiple vaccines, including those targeting Streptococcus pneumoniae, Haemophilus influenzae type b, and seasonal influenza [18, 81]. These responses are often characterized by reduced serum antibody titers, shorter durations of protective immunity, limited generation of memory B cells, and inefficient T follicular helper (Tfh) cell cooperation [10, 53, 81]. The immunological profile of DS, defined by partial immunodeficiency, altered thymic output, and accelerated immunosenescence, is likely to contribute to these vaccine response abnormalities [114]. Available evidence also suggests that, although initial seroconversion may occur, the magnitude and persistence of vaccine-induced antibody responses are reduced in DS compared with controls [115–117]. A quantitative immunological study found that children with DS had significantly fewer class-switched memory B cells and lower levels of CD19⁺ B cells than siblings and community controls. They also showed a suboptimal response to the pneumococcal polysaccharide vaccine despite comparable responses to the inactivated influenza vaccine [114]. These findings are consistent with an impaired capacity to generate effective T cell-independent responses, while relatively preserving T-dependent humoral responses in individuals with DS. Classical and Polysaccharide Vaccines For classical T-dependent vaccines (e.g., toxoids, inactivated influenza), seroconversion rates in individuals with DS are often comparable to controls, suggesting that initial B-cell activation can occur [114, 118]. However, qualitative differences persist: individuals with DS show reduced class-switched memory B cells, lower antibody quality, and weaker humoral expansion, consistent with impaired germinal center reactions [114, 118]. With polysaccharide vaccines, data are limited but informative. A study of Brazilian children with DS who were vaccinated with the 23-valent pneumococcal polysaccharide vaccine found that all participants showed increased serotype-specific IgG levels post-vaccination. Still, levels were lower in DS children than in age-matched controls for most serotypes [119]. Another immunological analysis in older children and adults with DS found adequate opsonophagocytic antibody titers in most cases following both conjugate and polysaccharide pneumococcal vaccination, suggesting that anti-polysaccharide responses may not be uniformly impaired [120]. However, broader immunological data indicate that DS may be associated with lower seroconversion to specific capsular polysaccharide antigens and may potentially benefit from conjugate vaccine platforms that engage T-cell help more effectively than T-independent polysaccharide antigens [121]. Pneumococcal conjugate vaccines might therefore be immunologically preferable over polysaccharide vaccines alone in DS due to enhanced T-dependent pathways, improved durability, and broader functional antibody responses. SARS-CoV-2 Vaccination (mRNA and Vector-based) A growing body of clinical evidence characterizes the immune response to SARS-CoV-2 vaccination in individuals with DS [122]. Multiple studies have shown that although individuals with DS generate measurable antibody responses and specific T-cell activation after mRNA- and vector-based COVID-19 vaccines, the magnitude and kinetics differ from those of non-DS controls [116, 122, 123]. Humoral studies indicate that anti-RBD and anti-Spike IgG titers are lower in DS than in age-matched controls at multiple time points after vaccination, and that antibody levels decline more rapidly over 6 months [116, 122, 123]. Specifically, mean post-second-dose RBD IgG levels in DS were lower than in controls and showed a steeper decline by six months, suggesting less durable humoral responses [116, 122, 123]. Streng et al. (2022) confirmed this pattern in a large cohort, with particularly reduced titers noted in individuals older than 40 years [115]. Cellular analyses support these findings. SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells with a predominant Th1 phenotype are induced in DS individuals after vaccination, and circulating Tfh cells increase post-immunization, indicating activation of cellular immunity [117, 122]. In a prospective study, adults with DS displayed SARS-CoV-2 antigen-specific T-cell responses after mRNA and vector vaccines, including IFN-γ production upon peptide restimulation, despite an underlying naïve lymphocyte deficit [122]. Booster vaccinations with additional mRNA doses have been shown to increase both antibody and cellular responses, supporting the use of enhanced vaccination schedules in this group [124]. These data suggest that although individuals with DS can mount specific immune responses to SARS-CoV-2 vaccination, these responses are often quantitatively lower and may be less durable compared with those observed in non-DS populations. Conclusions and Future Directions Individuals with DS exhibit a distinctive immune phenotype characterized by chronic interferon-driven activation, altered innate and adaptive responses, and features of accelerated immunosenescence. This immune landscape is associated with an increased susceptibility to respiratory viral infections and with relatively less robust and durable vaccine-induced immunity. The disproportionate burden of infections such as RSV, influenza, and SARS-CoV-2 in DS highlights the clinical relevance of these immune alterations and reveals important gaps in current preventive strategies. While individuals with DS can mount both humoral and cellular responses to vaccination, these responses often differ quantitatively and qualitatively from those observed in euploid populations, with implications for the level and persistence of protection. These observations suggest that standard vaccination approaches may not fully account for the unique immunological context of DS. A more tailored framework that considers underlying immune dysregulation, age-related changes, and comorbidity patterns may be needed to improve protective efficacy. In this context, longitudinal evaluation of vaccine responses and the development of optimized immunization strategies remain important priorities. Despite the growing body of evidence, several limitations should be acknowledged. Much of the available data on immune dysregulation in DS derive from heterogeneous study designs, including cross-sectional analyses, relatively small cohorts, and translational or experimental models, which may limit direct comparability and causal interpretation. In addition, variability in age, comorbidities, and clinical phenotypes across studies contributes to differences in reported findings. While interferon hyperactivation provides a coherent mechanistic framework, its precise contribution to specific clinical outcomes, including susceptibility to infection and vaccine responsiveness, remains incompletely defined and warrants further investigation. Future research should focus on refining the mechanistic understanding of immune dysfunction in DS, particularly the role of interferon signaling and its interaction with adaptive immune pathways. Such efforts may help inform the design of more effective vaccines and adjunctive preventive strategies to reduce the burden of respiratory infections in this vulnerable population. Author Contributions S.S-H and E.G-M equally contributed to conceptualization, investigation, drafting of the original manuscript, review and editing, and visualization. P.A.G, S.M.B, and A.M.K contributed to conceptualization, supervision, validation, review and editing, and funding acquisition. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. Funding This study was supported by grant 23CTEC-250091 from Corporación de Fomento de la Producción (INNOVA-CORFO) program of the Chilean Ministry of Economy, the Millennium Institute on Immunology and Immunotherapy (ICN2021_045) from the Agencia Nacional de Investigación y Desarrollo de Chile (ANID), and FONDECYT Regular grants N°1231851 (A.M.K), N°1240971 (P.A.G), and N°1231905 (S.M.B) from ANID. Data Availability No datasets were generated or analysed during the current study. Declarations Ethics Approval and Consent to Participate Ethics, Consent to Participate, and Consent to Publish declarations: not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Sofía Solari-Hernández and Enrique González-Madrid contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.